Attached files

file filename
8-K - 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20160203x8k.htm
EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20160203xex992.htm
EX-5.1 - EX-5.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20160203ex5132ed025.htm

Exhibit 99.1

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

 

Consolidated Balance Sheets

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

(in thousands, except per share amounts)

2015

 

2014

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

33,629 

 

$

36,449 

Investments

 

48,641 

 

 

64,899 

Accounts receivable

 

5,245 

 

 

3,406 

Inventory

 

10,955 

 

 

11,335 

Prepaid expenses and other current assets

 

12,071 

 

 

1,671 

Total current assets

 

110,541 

 

 

117,760 

Property and equipment, net

 

8,548 

 

 

6,601 

Long-term restricted cash

 

4,500 

 

 

 —

Other long-term assets

 

7,518 

 

 

29 

Total assets

$

131,107 

 

$

124,390 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

$

4,749 

 

$

5,608 

Accrued expenses

 

15,551 

 

 

11,441 

Deferred service revenue, current

 

6,815 

 

 

6,121 

Deferred contractual revenue, current

 

10,822 

 

 

6,785 

Other liabilities, current

 

241 

 

 

1,534 

Total current liabilities

 

38,178 

 

 

31,489 

Deferred service revenue, non-current

 

1,143 

 

 

1,129 

Deferred contractual revenue, non-current

 

1,312 

 

 

19,735 

Other liabilities, non-current

 

1,386 

 

 

2,153 

Notes payable

 

14,948 

 

 

13,991 

Financing derivative

 

600 

 

 

944 

Total liabilities

 

57,567 

 

 

69,441 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred Stock, $0.001 par value:

 

 

 

 

 

Authorized 50,000 shares; No shares issued or outstanding

 

 —

 

 

 —

Common Stock, $0.001 par value:

 

 

 

 

 

Authorized 1,000,000 shares; Issued and outstanding 79,983 and 73,927 shares at December 31, 2015 and 2014, respectively

 

80 

 

 

74 

Additional paid-in-capital

 

786,636 

 

 

736,339 

Accumulated other comprehensive income (loss)

 

(7)

 

 

Accumulated deficit

 

(713,169)

 

 

(681,473)

Total stockholders’ equity

 

73,540 

 

 

54,949 

Total liabilities and stockholders’ equity

$

131,107 

 

$

124,390 

 

 

 


 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

 

Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Years ended December 31,

(in thousands, except per share amounts)

2015

 

2014

 

2013

Revenue:

 

 

 

 

 

 

 

 

Product revenue

$

37,502 

 

$

35,299 

 

$

20,039 

Service and other revenue

 

10,896 

 

 

8,511 

 

 

6,446 

Contractual revenue

 

44,384 

 

 

16,784 

 

 

1,696 

Total revenue

 

92,782 

 

 

60,594 

 

 

28,181 

Cost of Revenue:

 

 

 

 

 

 

 

 

Cost of product revenue

 

30,704 

 

 

29,626 

 

 

15,706 

Cost of service and other revenue

 

8,628 

 

 

7,566 

 

 

6,056 

Total cost of revenue

 

39,332 

 

 

37,192 

 

 

21,762 

Gross profit

 

53,450 

 

 

23,402 

 

 

6,419 

Operating Expense:

 

 

 

 

 

 

 

 

Research and development

 

60,440 

 

 

48,230 

 

 

45,217 

Sales, general and administrative

 

45,187 

 

 

38,026 

 

 

38,745 

Gain on lease amendments

 

(23,043)

 

 

 —

 

 

 —

Total operating expense

 

82,584 

 

 

86,256 

 

 

83,962 

Operating loss

 

(29,134)

 

 

(62,854)

 

 

(77,543)

Interest expense

 

(2,926)

 

 

(2,828)

 

 

(2,478)

Other income (expense), net

 

364 

 

 

(478)

 

 

728 

Net loss

 

(31,696)

 

 

(66,160)

 

 

(79,293)

Other comprehensive loss:

 

 

 

 

 

 

 

 

Unrealized loss on investments

 

(16)

 

 

(5)

 

 

(16)

Comprehensive loss

$

(31,712)

 

$

(66,165)

 

$

(79,309)

Net loss per share:

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.42)

 

$

(0.94)

 

$

(1.26)

Shares used in computing basic and diluted net loss per share

 

75,614 

 

 

70,475 

 

 

62,784 

 

 

 

 

 

 


 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

 

Consolidated Statements of Cash Flows

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

(in thousands)

2015

 

2014

 

2013

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

$

(31,696)

 

$

(66,160)

 

$

(79,293)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Depreciation and amortization

 

3,677 

 

 

4,221 

 

 

5,648 

Amortization of debt discount and financing costs

 

957 

 

 

793 

 

 

595 

Stock-based compensation

 

13,840 

 

 

9,943 

 

 

9,905 

Non-cash portion of gain on lease amendments

 

(3,043)

 

 

 —

 

 

 —

Other items

 

(230)

 

 

507 

 

 

(352)

Changes in assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable

 

(1,738)

 

 

(660)

 

 

76 

Inventory

 

(2,466)

 

 

(1,285)

 

 

(60)

Prepaid expenses and other assets

 

(17,889)

 

 

(224)

 

 

840 

Accounts payable

 

(716)

 

 

3,891 

 

 

(1,271)

Accrued expenses 

 

5,732 

 

 

3,536 

 

 

1,327 

Deferred service revenue

 

708 

 

 

2,686 

 

 

386 

Deferred contractual revenue

 

(14,386)

 

 

(6,784)

 

 

33,304 

Other liabilities

 

(639)

 

 

(1,932)

 

 

(938)

Net cash used in operating activities

 

(47,889)

 

 

(51,468)

 

 

(29,833)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

(3,009)

 

 

(1,609)

 

 

(909)

Proceeds from disposal of property and equipment

 

36 

 

 

 —

 

 

 —

Long-term restricted cash 

 

(4,500)

 

 

 —

 

 

 —

Purchase of investments

 

(84,579)

 

 

(126,413)

 

 

(201,547)

Sales of investments

 

8,317 

 

 

 —

 

 

100 

Maturities of investments

 

92,341 

 

 

147,586 

 

 

169,239 

Net cash provided by (used in) investing activities

 

8,606 

 

 

19,564 

 

 

(33,117)

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

7,363 

 

 

3,968 

 

 

3,079 

Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs

 

29,100 

 

 

38,023 

 

 

19,927 

Proceeds from issuance of debt agreement, net of issuance costs

 

 —

 

 

 —

 

 

19,766 

Net cash provided by financing activities

 

36,463 

 

 

41,991 

 

 

42,772 

Net increase (decrease) in cash and cash equivalents

 

(2,820)

 

 

10,087 

 

 

(20,178)

Cash and cash equivalents at beginning of period

 

36,449 

 

 

26,362 

 

 

46,540 

Cash and cash equivalents at end of period

$

33,629 

 

$

36,449 

 

$

26,362 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

Interest paid

$

1,794 

 

$

1,794 

 

$

1,165 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

Inventory transferred to (from) property and equipment

 

2,846 

 

 

 —

 

 

(558)